Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Gross Profit (2019 - 2025)

Coherus Oncology (CHRS) has disclosed Gross Profit for 7 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 74.65% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.4 million through Dec 2025, up 60.56% year-over-year, with the annual reading at $28.4 million for FY2025, 60.56% up from the prior year.
  • Gross Profit hit $8.7 million in Q4 2025 for Coherus Oncology, up from $7.8 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $75.5 million in Q1 2021 to a low of $869000.0 in Q1 2024.
  • Historically, Gross Profit has averaged $27.7 million across 5 years, with a median of $12.9 million in 2022.
  • Biggest five-year swings in Gross Profit: plummeted 94.42% in 2024 and later surged 469.16% in 2025.
  • Year by year, Gross Profit stood at $61.3 million in 2021, then crashed by 49.16% to $31.2 million in 2022, then tumbled by 77.67% to $7.0 million in 2023, then dropped by 28.37% to $5.0 million in 2024, then soared by 74.65% to $8.7 million in 2025.
  • Business Quant data shows Gross Profit for CHRS at $8.7 million in Q4 2025, $7.8 million in Q3 2025, and $6.9 million in Q2 2025.